ZA200703450B - Formulations comprising ecteinascidin and a disaccharide - Google Patents

Formulations comprising ecteinascidin and a disaccharide

Info

Publication number
ZA200703450B
ZA200703450B ZA200703450A ZA200703450A ZA200703450B ZA 200703450 B ZA200703450 B ZA 200703450B ZA 200703450 A ZA200703450 A ZA 200703450A ZA 200703450 A ZA200703450 A ZA 200703450A ZA 200703450 B ZA200703450 B ZA 200703450B
Authority
ZA
South Africa
Prior art keywords
ecteinascidin
disaccharide
formulations
Prior art date
Application number
ZA200703450A
Other languages
English (en)
Inventor
Salve Pilar Calvo
Bastiaan Nuijen
Barreira Maria Tobio
Jacob Hendrik Beijnen
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703450(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of ZA200703450B publication Critical patent/ZA200703450B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
ZA200703450A 2004-10-29 2007-04-26 Formulations comprising ecteinascidin and a disaccharide ZA200703450B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62381304P 2004-10-29 2004-10-29

Publications (1)

Publication Number Publication Date
ZA200703450B true ZA200703450B (en) 2008-09-25

Family

ID=35432682

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703450A ZA200703450B (en) 2004-10-29 2007-04-26 Formulations comprising ecteinascidin and a disaccharide

Country Status (37)

Country Link
US (2) US8895557B2 (zh)
EP (1) EP1658848B1 (zh)
JP (1) JP4268163B2 (zh)
KR (1) KR101188691B1 (zh)
CN (2) CN1823794A (zh)
AR (2) AR051653A1 (zh)
AT (1) ATE368461T1 (zh)
AU (1) AU2005227421B2 (zh)
BR (1) BRPI0517238B1 (zh)
CA (1) CA2520979C (zh)
CY (1) CY1107773T1 (zh)
DE (1) DE602005001833T2 (zh)
DK (1) DK1658848T3 (zh)
ES (1) ES2290844T3 (zh)
GT (1) GT200500314A (zh)
HK (1) HK1091724A1 (zh)
HN (1) HN2005029978A (zh)
HR (1) HRP20070374T3 (zh)
IL (1) IL182776A (zh)
JO (1) JO2464B1 (zh)
MX (1) MXPA05011650A (zh)
MY (1) MY139049A (zh)
NO (1) NO328035B1 (zh)
NZ (1) NZ554761A (zh)
PA (1) PA8650801A1 (zh)
PE (2) PE20060925A1 (zh)
PL (1) PL1658848T3 (zh)
PT (1) PT1658848E (zh)
RS (1) RS50510B (zh)
RU (1) RU2382647C2 (zh)
SI (1) SI1658848T1 (zh)
SV (1) SV2006002283A (zh)
TW (1) TWI296523B (zh)
UA (1) UA91032C2 (zh)
UY (1) UY29183A1 (zh)
WO (1) WO2006046079A1 (zh)
ZA (1) ZA200703450B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
NZ525730A (en) * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
PL1658848T3 (pl) 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
PL2701720T3 (pl) * 2011-04-28 2017-12-29 Oncopeptides Ab Liofilizowany preparat cytotoksycznych dipeptydów
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN106880592B (zh) * 2015-12-15 2021-04-06 江苏恒瑞医药股份有限公司 一种曲贝替定的纳米乳及其制备方法
EP3412293A4 (en) 2016-02-04 2019-10-16 Jiangsu Hengrui Medicine Co., Ltd. INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING TRABECTEDINE FOR EXTERNAL USE AT THE GASTROINTESTINAL LEVEL, AND METHOD OF MANUFACTURING THE SAME
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20210169873A1 (en) * 2019-10-21 2021-06-10 RK Pharma Solutions LLC Storage-stable ready-to-use injectable formulations of Trabectedin
KR20220119618A (ko) * 2019-11-21 2022-08-30 파르마 마르, 에스.에이. 루비넥테딘 제형으로 소세포폐암을 치료하는 방법
CA3176956A1 (en) 2020-04-15 2021-10-21 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid
US20230226051A1 (en) * 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
ATE69234T1 (de) * 1986-06-09 1991-11-15 Univ Illinois Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) * 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AU7589898A (en) 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
CA2327468C (en) 1998-04-06 2008-05-06 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
US6316214B1 (en) 1998-05-11 2001-11-13 The Board Of Trustees Of The University Of Illinois ETM-775 metabolite of ecteinascidin 743
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) * 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
ATE314084T1 (de) * 2000-10-31 2006-01-15 Pharma Mar Sa Kahalalid f formulierung
CA2447553A1 (en) 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
NZ525730A (en) 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
HUP0302567A2 (hu) * 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002076459A1 (en) 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
AU2004291037A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
PL1658848T3 (pl) 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
WO2007062413A2 (en) * 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
PL1658848T3 (pl) 2007-12-31
CN102018714B (zh) 2014-01-08
BRPI0517238B1 (pt) 2021-11-09
RS50510B (sr) 2010-03-02
MY139049A (en) 2009-08-28
RU2007119724A (ru) 2008-12-10
SV2006002283A (es) 2006-07-20
PT1658848E (pt) 2007-11-05
AR051653A1 (es) 2007-01-31
CA2520979A1 (en) 2006-02-15
KR101188691B1 (ko) 2012-10-09
HRP20070374T3 (en) 2007-10-31
TWI296523B (en) 2008-05-11
TW200621256A (en) 2006-07-01
PE20100089A1 (es) 2010-03-01
AU2005227421B2 (en) 2007-06-28
PA8650801A1 (es) 2006-09-22
US8895557B2 (en) 2014-11-25
DE602005001833T2 (de) 2008-04-17
CA2520979C (en) 2009-03-24
BRPI0517238A (pt) 2008-10-07
WO2006046079A1 (en) 2006-05-04
UA91032C2 (en) 2010-06-25
PE20060925A1 (es) 2006-10-23
US20060094687A1 (en) 2006-05-04
NO20072713L (no) 2007-07-19
EP1658848A1 (en) 2006-05-24
JP2006124393A (ja) 2006-05-18
NZ554761A (en) 2010-01-29
AR110986A2 (es) 2019-05-22
ES2290844T3 (es) 2008-02-16
HK1091724A1 (en) 2007-01-26
CN1823794A (zh) 2006-08-30
UY29183A1 (es) 2006-05-31
IL182776A0 (en) 2007-08-19
US10322183B2 (en) 2019-06-18
US20150094313A1 (en) 2015-04-02
AU2005227421A1 (en) 2006-05-18
DK1658848T3 (da) 2007-11-26
CY1107773T1 (el) 2013-06-19
SI1658848T1 (sl) 2007-12-31
MXPA05011650A (es) 2006-05-17
RU2382647C2 (ru) 2010-02-27
ATE368461T1 (de) 2007-08-15
JO2464B1 (en) 2009-01-20
IL182776A (en) 2010-06-30
HN2005029978A (es) 2009-10-27
DE602005001833D1 (de) 2007-09-13
CN102018714A (zh) 2011-04-20
GT200500314A (es) 2007-03-22
EP1658848B1 (en) 2007-08-01
KR20070091121A (ko) 2007-09-07
NO328035B1 (no) 2009-11-10
JP4268163B2 (ja) 2009-05-27

Similar Documents

Publication Publication Date Title
HK1091724A1 (en) Formulations comprising ecteinascidin and a disaccharide
IL180762A (en) Oligomer-insulin conjugates, formulations containing them and their use
EP1804831A4 (en) VACCINES BASED ON LLO AND LISTERIA
GB0413730D0 (en) A pharmaceutical composition and its use
IL179795A0 (en) A pharmaceutical composition and its use
HK1101911A1 (en) Tetrahydrocarbozoles and derivatives
IL177566A0 (en) Pharmaceutical formulations
AP2006003768A0 (en) TetraazabenzoÄeÜazulene derivatives and analogs tehereof
EP1731506A4 (en) 5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
GB0426301D0 (en) Pharmaceutical formulations
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
IL177826A0 (en) Oral matrix formulations comprising licarbazepine
ZA200610032B (en) Oculoselective drugs and prodrugs
IL181300A0 (en) Photosensitizer formulations and uses thereof
PT1812072E (pt) Formulações de benzotiazole e sua utilização
GB0416397D0 (en) Pharmaceutical formulations
EP1810976A4 (en) BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
GB0406048D0 (en) Drug formulations
ZA200703998B (en) Benzothiazole formulations and use thereof
GB0406014D0 (en) Pharmaceutical composition and use
EP1841406A4 (en) METHOD AND FORMULATIONS
GB0414260D0 (en) Form and function fillings
EP1759703A4 (en) IMMUNOSTIMULATING AGENT AND INTERF ROGEN
GB0418932D0 (en) Helicopter-with tracked-launch and tunaround pad-vehicle design principles
IL165458A0 (en) And